%0 Journal Article %A DAINIUS CHARACIEJUS %A VITA PAŠUKONIENĖ %A JOHN J.L. JACOBS %A RIMANTAS EIDUKEVIČIUS %A FELIKSAS JANKEVIČIUS %A NERINGA DOBROVOLSKIENĖ %A MYKOLAS MAURICAS %A R. JEROEN A. VAN MOORSELAAR %A WILLEM DEN OTTER %T Prognostic Significance of Peripheral Blood CD8highCD57+ Lymphocytes in Bladder Carcinoma Patients After Intravesical IL-2 %D 2011 %J Anticancer Research %P 699-703 %V 31 %N 2 %X Background: The objective of this study was to evaluate the recurrence-preventing effect of intravesical instillations of interleukin-2 (IL-2) in patients with non-muscle-invasive bladder carcinoma. In addition, this study aimed to determine the significance of immune parameters for recurrence-free interval. Patients and Methods: Twenty-six patients with non-muscle-invasive bladder carcinoma were treated with intravesical instillations of IL-2 (Proleukin®, Novartis, formerly Chiron) in doses of 9×106 IU on 5 consecutive days, beginning on the second day after transurethral resection (TUR) of tumours. CD8highCD57+ lymphocytes in peripheral blood were determined before TUR and compared with the recurrence-free interval after treatment. Results: The multivariate analysis showed that CD8highCD57+ lymphocytes had a prognostic significance in combination with number of bladder tumours, prior recurrence rate and age of patients. Conclusion: Peripheral blood CD8highCD57+ lymphocytes have prognostic significance for recurrence-free survival in patients with non-muscle-invasive bladder carcinoma after TUR and intravesical IL-2. %U https://ar.iiarjournals.org/content/anticanres/31/2/699.full.pdf